True North News

📔 Topics ℹ️ About

Topic: Genetic Medicine and Precision Therapies

Genetic Medicine and Precision Therapies

2 Stories

3 Related Topics

📊 Analysis Summary

Alternative Data 8 Facts

Mainstream coverage this week focused on two developments in genetic and precision therapies for ALS: the start of a Phase 3 trial of pridopidine to slow disease progression, and Columbia University’s experimental antisense‑style spinal infusions targeting a rare FUS mutation used preventively in a high‑risk carrier (Jeff Vierstra) whose early EMG abnormalities resolved and who remains symptom‑free three years later. Reports emphasized the experimental nature of the work, physician optimism (Dr. Neil Shneider), and Columbia’s Silence ALS initiative to extend individualized gene‑based approaches, while noting that most ALS is not familial and that these are early, hopeful signals rather than definitive proof.

What mainstream pieces largely omitted were broader factual and equity contexts revealed in alternative research: FUS mutations account for only a small share of familial ALS (~3.2%), sporadic ALS heritability may be high (~61%), and U.S. trials have historically under‑enrolled non‑White participants (past studies ~95% Caucasian), with Black patients more often diagnosed younger (about 26% before age 50 versus 12.9% for White patients) and differing prevalence/mortality patterns across racial groups. Also missing were explicit caveats about the anecdotal nature of single‑patient results, long‑term safety and efficacy unknowns, and practical access/justice issues for individualized gene therapies. No contrarian analyses or organized dissenting viewpoints were identified in the material reviewed.

Summary generated: April 10, 2026 at 11:12 PM

Phase 3 Pridopidine Trial for ALS Begins Enrollment

7d Developing 2

A Phase 3 clinical trial of pridopidine has begun enrolling people with ALS to test whether the drug can slow disease progression. Separately, Columbia University researchers report promising early results from an experimental antisense‑style therapy targeting a rare FUS mutation — including one patient whose EMG abnormalities normalized and who remains symptom‑free three years later — prompting optimism from Dr. Neil Shneider and supporting Columbia’s Silence ALS initiative to develop individualized gene‑based treatments.

Columbia Neurologists Test Preventive Gene Therapy in Familial ALS Carrier

A CBS News report profiles 41‑year‑old scientist Jeff Vierstra, a U.S. man from a family ravaged by a rare FUS gene mutation that causes early‑onset ALS, who has spent the past three years receiving experimental spinal infusions at Columbia University in what his neurologist calls the first known attempt to prevent ALS in a high‑risk carrier. Led by Dr. Neil Shneider at Columbia’s Eleanor and Lou Gehrig ALS Center, the treatment uses an agent that targets and disables the mutated FUS gene; after early EMG tests showed mild abnormalities suggestive of incipient disease, Vierstra’s muscle‑signal readings normalized within a year and he remains free of ALS symptoms, even as his two sisters, who also received the therapy after symptom onset, ultimately died of the disease. The piece notes that only 10–15% of ALS cases are genetic but about two‑thirds of those are familial, and that an estimated 35,000 Americans live with ALS, underscoring why researchers see pre‑symptomatic gene‑based interventions as a potential pivot from fatal prognosis to chronic management. Shneider cautions that the work is still experimental but calls it "a very big deal" and says his team is expanding efforts through Silence ALS, a program seeking patients with other rare genetic forms of ALS for individualized gene‑targeted therapies, a development already stirring cautious hope and questions about access among U.S. ALS families and advocacy groups online.